This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holst, B. Articles by Schwartz, T. W. Search for Related Content PubMed PubMed Citation Articles by Holst, B. Articles by Schwartz, T. W.

Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling

Laboratory for Molecular Pharmacology (B.H., E.B., A.B., T.W.S.), Department of Pharmacology, The Panum Institute, University of Copenhagen, DK-2200 Copenhagen, Denmark; and 7TM Pharma A/S (A.H., T.W.S.), 2970 Hørsholm, Denmark

Address all correspondence and requests for reprints to: Birgitte Holst, M.D., Ph.D., Laboratory for Molecular Pharmacology, Department of Pharmacology, The Panum Institute, Blegdamsvej 3, DK-2200, Copenhagen, Denmark. E-mail: b.holst{at}molpharm.dk.

Two nonpeptide (L692,429 and MK-677) and two peptide [GH-releasing peptide (GHRP)-6 and ghrelin] agonists were compared in binding and in signal transduction assays: calcium mobilization, inositol phosphate turnover, cAMP-responsive element (CRE), and serum-responsive element (SRE) controlled transcription, as well as arrestin mobilization. MK-677 acted as a simple agonist having an affinity of 6.5 nM and activated all signal transduction systems with similar high potency (0.2–1.4 nM). L-692,429 also displayed a very similar potency in all signaling assays (25–60 nM) but competed with a 1000-fold lower apparent affinity for ghrelin binding and surprisingly acted as a positive allosteric receptor modulator by increasing ghrelin’s potency 4- to 10-fold. In contrast, the potency of GHRP-6 varied 600-fold (0.1–61 nM) depending on the signal transduction assay, and it acted as a negative allosteric modulator of ghrelin signaling. Unexpectedly, the maximal signaling efficacy for ghrelin was increased above what was observed with the hormone itself during coadministration with the nonendogenous agonists. It is concluded that agonists for the ghrelin receptor vary both in respect of their intrinsic agonist properties and in their ability to modulate ghrelin signaling. A receptor model is presented wherein ghrelin normally only activates one receptor subunit in a dimer and where the smaller nonendogenous agonists bind in the other subunit to act both as coagonists and as either neutral (MK-677), positive (L-692,429), or negative (GHRP-6) modulators of ghrelin function. It is suggested that an optimal drug candidate could be an agonist that also is a positive modulator of ghrelin signaling.

This article has been cited by other articles:

				P. S. Petersen, D. P. D. Woldbye, A. N. Madsen, K. L. Egerod, C. Jin, M. Lang, M. Rasmussen, A. G. Beck-Sickinger, and B. Holst In Vivo Characterization of High Basal Signaling from the Ghrelin Receptor Endocrinology, November 1, 2009; 150(11): 4920 - 4930. [Abstract] [Full Text] [PDF]

				K. A. Bennett, C. J. Langmead, A. Wise, and G. Milligan Growth Hormone Secretagogues and Growth Hormone Releasing Peptides Act As Orthosteric Super-Agonists but Not Allosteric Regulators for Activation of the G Protein G{alpha}o1 by the Ghrelin Receptor Mol. Pharmacol., October 1, 2009; 76(4): 802 - 811. [Abstract] [Full Text] [PDF]

				B. Holst, T. M. Frimurer, J. Mokrosinski, T. Halkjaer, K. B. Cullberg, C. R. Underwood, and T. W. Schwartz Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor Mol. Pharmacol., January 1, 2009; 75(1): 44 - 59. [Abstract] [Full Text] [PDF]

				F. F. Casanueva, J. P. Camina, M. C. Carreira, Y. Pazos, J. L. Varga, and A. V. Schally Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a PNAS, December 23, 2008; 105(51): 20452 - 20457. [Abstract] [Full Text] [PDF]

				G. L. Fraser, H. R. Hoveyda, and G. S. Tannenbaum Pharmacological Demarcation of the Growth Hormone, Gut Motility and Feeding Effects of Ghrelin Using a Novel Ghrelin Receptor Agonist Endocrinology, December 1, 2008; 149(12): 6280 - 6288. [Abstract] [Full Text] [PDF]

				P. C. Jensen, S. Thiele, T. Ulven, T. W. Schwartz, and M. M. Rosenkilde Positive Versus Negative Modulation of Different Endogenous Chemokines for CC-chemokine Receptor 1 by Small Molecule Agonists through Allosteric Versus Orthosteric Binding J. Biol. Chem., August 22, 2008; 283(34): 23121 - 23128. [Abstract] [Full Text] [PDF]

				J.-N. Ma, H. H. Schiffer, A. E. Knapp, J. Wang, K. K. Wong, E. A. Currier, M. Owens, N. R. Nash, L. R. Gardell, M. R. Brann, et al. Identification of the Atypical L-Type Ca2+ Channel Blocker Diltiazem and Its Metabolites As Ghrelin Receptor Agonists Mol. Pharmacol., August 1, 2007; 72(2): 380 - 386. [Abstract] [Full Text] [PDF]

				B. Holst, J. Mokrosinski, M. Lang, E. Brandt, R. Nygaard, T. M. Frimurer, A. G. Beck-Sickinger, and T. W. Schwartz Identification of an Efficacy Switch Region in the Ghrelin Receptor Responsible for Interchange between Agonism and Inverse Agonism J. Biol. Chem., May 25, 2007; 282(21): 15799 - 15811. [Abstract] [Full Text] [PDF]

				B. Holst, M. Lang, E. Brandt, A. Bach, A. Howard, T. M. Frimurer, A. Beck-Sickinger, and T. W. Schwartz Ghrelin Receptor Inverse Agonists: Identification of an Active Peptide Core and Its Interaction Epitopes on the Receptor Mol. Pharmacol., September 1, 2006; 70(3): 936 - 946. [Abstract] [Full Text] [PDF]

				R M Luque, J R Peinado, F Gracia-Navarro, F Broglio, E Ghigo, R D Kineman, M M Malagon, and J P Castano Cortistatin mimics somatostatin by inducing a dual, dose-dependent stimulatory and inhibitory effect on growth hormone secretion in somatotropes. J. Mol. Endocrinol., June 1, 2006; 36(3): 547 - 556. [Abstract] [Full Text] [PDF]